Abstract

Descending controls on spinal nociceptive processing play a pivotal role in shaping the pain experience after tissue injury. Secondary hypersensitivity develops within undamaged tissue adjacent and distant to damaged sites. Spinal neuronal pools innervating regions of secondary hypersensitivity are dominated by descending facilitation that amplifies spinal inputs from unsensitized peripheral nociceptors. Cyclooxygenase-prostaglandin (PG) E2 signaling within the ventrolateral periaqueductal gray (vlPAG) is pronociceptive in naive and acutely inflamed animals, but its contributions in more prolonged inflammation and, importantly, secondary hypersensitivity remain unknown. In naive rats, PG EP3 receptor (EP3R) antagonism in vlPAG modulated noxious withdrawal reflex (EMG) thresholds to preferential C-nociceptor, but not A-nociceptor, activation and raised thermal withdrawal thresholds in awake animals. In rats with inflammatory arthritis, secondary mechanical and thermal hypersensitivity of the hindpaw developed and was associated with spinal sensitization to A-nociceptor inputs alone. In arthritic rats, blockade of vlPAG EP3R raised EMG thresholds to C-nociceptor activation in the area of secondary hypersensitivity to a degree equivalent to that evoked by the same manipulation in naive rats. Importantly, vlPAG EP3R blockade also affected responses to A-nociceptor activation, but only in arthritic animals. We conclude that vlPAG EP3R activity exerts an equivalent facilitation on the spinal processing of C-nociceptor inputs in naive and arthritic animals, but gains in effects on spinal A-nociceptor processing from a region of secondary hypersensitivity. Therefore, the spinal sensitization to A-nociceptor inputs associated with secondary hypersensitivity is likely to be at least partly dependent on descending prostanergic facilitation from the vlPAG. After tissue damage, sensitivity to painful stimulation develops in undamaged areas (secondary hypersensitivity). This is found in many painful conditions, particularly arthritis. The periaqueductal gray (PAG) is an important center that controls spinal nociceptive processing, on which secondary hypersensitivity depends. Prostaglandins (PGs) are mediators of inflammation with pronociceptive actions within the PAG under normal conditions. We find that secondary hindpaw hypersensitivity in arthritic rats results from spinal sensitization to peripheral A-nociceptor inputs. In the PAG of arthritic, but not naive, rats, there is enhanced control of spinal A-nociceptor processing through PG EP3 receptors. The descending facilitatory actions of intra-PAG PGs play a direct and central role in the maintenance of inflammatory secondary hypersensitivity, particularly relating to the processing of A-fiber nociceptive information.

Highlights

  • The midbrain periaqueductal gray (PAG) and downstream nuclei within the medulla and brainstem, such as the rostroventral medulla, form a descending pain modulatory system that can augment or inhibit spinal processing of nociceptive information

  • Blockade of the PG EP3 receptor (EP3R) within the ventrolateral periaqueductal gray (vlPAG) modulates withdrawal reflex thresholds in conscious naive rats We have previously shown that inhibition of COX in the vlPAG increases paw withdrawal thresholds in both awake rats (Leith et al, 2014) and anesthetized rats (Leith et al, 2007), suggesting a tonic PAG COX-dependent pronociceptive system

  • Delivery of the EP3R antagonist GW671021B into the vlPAG increased thermal paw withdrawal thresholds compared with both baseline and vehicle (EP3R antagonist baseline vs postdrug ϭ 44.9 Ϯ 0.1 vs 45.9 Ϯ 0.2°C, vehicle baseline vs postvehicle ϭ 44.4 Ϯ 0.3 vs 44.6 Ϯ 0.2°C; Fig. 1)

Read more

Summary

Introduction

The midbrain periaqueductal gray (PAG) and downstream nuclei within the medulla and brainstem, such as the rostroventral medulla, form a descending pain modulatory system that can augment or inhibit spinal processing of nociceptive information. R.A.R.D. and MRC Project Grant G0801381 to B.M.L.); the Biotechnology & Biological Sciences Research Council (BBSRC CASE Studentship with GSK to J.L.L.); Yarmouk University, Yarmouk University, Jordan (scholarship to F.A.); The Wellcome Trust (Grant 071335/Z/03/A to B.M.L.); Arthritis Research UK (Project Grant 20400 to L.F.D.); and by a Biotechnology and Biological Sciences Research Council/MRC/British Pharmacological Society Strategic Skills Award (L.F.D. and B.M.L.) Data included in this manuscript have been presented in abstract form at the British Neuroscience Association Meeting 2015, at the 37th International Union of Physiological Societies 2013, and are included in R.A.R.D.’s and J.L.L.’s doctoral theses (University of Bristol, UK, 2014 and 2008, respectively). We thank Drs Stella Koutsikou and Nicholas Beazley-Long for technical advice on experiments in this study

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call